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Somatostatin Receptors Signal through EFA6A-ARF6 to Activate
Phospholipase D in Clonal β-Cells
Abstract
Somatostatin (SS) is a peptide hormone that inhibits insulin secretion in β-cells by activating its Gi/o-coupled
receptors. Our previous work indicated that a βγ-dimer of Gi/o coupled to SS receptors can activate
phospholipase D1 (PLD1) (Cheng, H., Grodnitzky, J. A., Yibchok-anun, S., Ding, J., and Hsu, W. H. (2005)
Mol. Pharmacol. 67, 2162–2172). The aim of the present study was to elucidate the mechanisms underlying
SS-induced PLD activation. We demonstrated the presence of ADP-ribosylation factor Arf1 and Arf6 in clonal
β-cells, HIT-T15. We also determined that the activation of PLD1 was mediated through Arf6.
Overexpression of dominant-negative (dn) Arf6 mutant, Arf6(T27N), and suppression of mRNA levels using
siRNA, both abolished SS-induced PLD activation, while overexpression of wild type Arf6 further enhanced
this PLD activation. In contrast, overexpression of dn-Arf1 mutant Arf1(T31N) or dn-Arf5 mutant
Arf5(T31N) failed to reduce SS-induced PLD activation. These findings suggested that Arf6, but not Arf1 or
Arf5, mediates the effect of SS. We further determined the involvement of the Arf6 guanine nucleotide
exchange factor (GEF) EFA6A, a GEF previously thought to be found predominantly in the brain, in the
activation of PLD1 in HIT-T15 cells. Using Northern and Western blot analyses, both mRNA and protein of
EFA6A were found in these cells. Overexpression of dn-EFA6A mutant, EFA6A(E242K), and suppression of
mRNA levels using siRNA, both abolished SS-induced PLD activation, whereas overexpression of dn-EFA6B
mutant, EFA6B(E651K), failed to reduce SS-induced PLD activation. In addition, overexpression of dn-
ARNO mutant, ARNO(E156K), another GEF of Arf6, had no effect on SS-induced activation of PLD. Taken
together, these results suggest that SS signals through EFA6A to activate Arf6-PLD cascade.
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Somatostatin (SS) is a peptide hormone that inhibits insulin
secretion in-cells by activating its Gi/o-coupled receptors. Our
previous work indicated that a -dimer of Gi/o coupled to SS
receptors can activate phospholipase D1 (PLD1) (Cheng, H.,
Grodnitzky, J. A., Yibchok-anun, S., Ding, J., and Hsu, W. H.
(2005)Mol. Pharmacol. 67, 2162–2172). The aim of the present
study was to elucidate the mechanisms underlying SS-induced
PLD activation.We demonstrated the presence of ADP-ribosyl-
ation factor Arf1 and Arf6 in clonal -cells, HIT-T15. We also
determined that the activation of PLD1 was mediated through
Arf6. Overexpression of dominant-negative (dn) Arf6 mutant,
Arf6(T27N), and suppression ofmRNA levels using siRNA, both
abolished SS-induced PLD activation, while overexpression of
wild type Arf6 further enhanced this PLD activation. In con-
trast, overexpression of dn-Arf1mutant Arf1(T31N) or dn-Arf5
mutantArf5(T31N) failed to reduce SS-inducedPLDactivation.
These findings suggested that Arf6, but not Arf1 or Arf5, medi-
ates the effect of SS. We further determined the involvement of
the Arf6 guanine nucleotide exchange factor (GEF) EFA6A, a
GEF previously thought to be found predominantly in the brain,
in the activation of PLD1 in HIT-T15 cells. Using Northern and
Western blot analyses, both mRNA and protein of EFA6A were
found in these cells. Overexpression of dn-EFA6A mutant,
EFA6A(E242K), and suppression of mRNA levels using siRNA,
both abolished SS-inducedPLDactivation,whereas overexpres-
sion of dn-EFA6B mutant, EFA6B(E651K), failed to reduce
SS-induced PLD activation. In addition, overexpression of dn-
ARNO mutant, ARNO(E156K), another GEF of Arf6, had no
effect on SS-induced activation of PLD. Taken together, these
results suggest that SS signals through EFA6A to activate Arf6-
PLD cascade.
Somatostatin (SS)3 is a peptide hormone that is well known
for its ability to inhibit the secretion of growth hormone, glu-
cagon, and insulin (1, 2). This peptide hormone is secreted from
many tissues in the body including the pancreatic -cells (1, 2).
SS secreted from -cells exerts an inhibitory paracrine effect on
insulin secreting-cells and is released in two sizes; a 14-amino
acid peptide and its prohormoneNH2-terminal extended form,
a 28-amino acid peptide (1, 2). There are six SS receptors, all of
which are G-protein coupled receptors (GPCRs) (3, 4), which
couple through Gi/o. SS transduces its physiological signal
through many effectors, which include adenylyl cyclase (5),
inwardly rectifying K channels (6), tyrosine phosphatase (7),
phospholipase C (8), voltage-dependent Ca2 channel (9),
Na-H antiporter (10), and mitogen-activated protein kinase
(11).We recently reported that SS can activate phospholipaseD
(PLD), causing a subsequent increase in phosphoinositol 4,5-
bisphosphate (PIP2) concentration (12). This receptor-medi-
ated activation of PLD was attributed to the release of the
-dimer coupled to SS-receptors and occurred in a pertussis
toxin-sensitive manner. We also demonstrated that PLD1 was
the only detectable isoform present in the clonal -cells HIT-
T15 and the downstream stimulatory effects of SS onPIP2 levels
and intracellular Ca2 concentration ([Ca2]i) could be attrib-
uted to the activation of PLD1 (12).
PLD Hydrolyzes Phosphatidylcholine to phosphatidic acid.
The conversion of phosphatidylcholine to phosphatidic acid
regulatesmany cellular processes such as endocytosis, exocyto-
sis, cell proliferation, and cell migration (13–17). There are two
mammalian PLD isoforms, PLD1 and PLD2. These isoforms
differ in their subcellular location and regulation. PLD1 is
located in the cytosol, Golgi apparatus, nucleus, and plasma
membrane,while PLD2 seems to be largely foundon the plasma
membrane (18). Each isoform may exist as one of two splice
variants, i.e. PLD1a, PLD1b, PLD2a, and PLD2b (19, 20). There
are many potential regulators for PLD, but only a few of them
can stimulate both isoforms. For example, themembrane phos-
pholipids, PIP2, and protein kinase C (PKC) stimulate both iso-
forms of PLD (21, 22). The family of small G-proteins, ADP-ri-
bosylation factor (Arf), and Rho are potent stimulators of PLD1
but are unable to stimulate the endogenous forms of PLD2 (23).
PLD activity can also be stimulated by the activation of various
GPCRs. A plethora of GPCR agonists have been shown to stim-
ulate PLD activity. Angiotensin II (24), bradykinin (25), carba-
chol (26), lysophosphatidic acid (27), gonadotropin-releasing
hormone (28), vasopressin (29), endothelin (30), thyrotropin
(31), and prostaglandin F2 (32) are examples of the prevalent
nature of GPCR-mediated stimulation of PLD. GPCRs can
stimulate PLD through phospholipase C (PLC)-dependent sig-
naling pathway. PLC catalyzes the conversion of PIP2 to inositol
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1,4,5-trisphosphate and diacylglycerol. Inositol 1,4,5-trisphos-
phate mobilizes Ca2 from endoplasmic reticulum stores. This
increase in [Ca2]i is known to activate conventional isoforms
of PKC.Diacylglycerol, the other product of PLCactivation, can
also stimulate PKC through its interaction with the C1 domain
of the conventional and novel PKC isoforms. Both PKC iso-
forms are known to enhance the activity of PLD. GPCR activa-
tion of small G-proteins can be involved in stimulating PLD (6,
11). The signaling mechanisms responsible for small G-protein
regulation of PLD are diverse, but two small G-proteins, Rho
and Arf, have been firmly established to regulate PLD activity
throughGPCRs (26, 32–36). Stimulation of Rho by activation of
GPCRs is attributed to the associated -dimer binding to the
pleckstrin homology-domain of a guanine nucleotide exchange
factor for Rho (37) and its direct interaction with G12/13-sub-
unit (38, 39). These interactions cause GDP to dissociate from
Rho, which allows Rho to bind GTP, switching it to the active
form. Rho-GTP binds to the COOH terminus of PLD1. InHIT-
T15 cells, activation of SS receptors stimulates PLD activity and
subsequently increases PIP2 synthesis to provide additional
substrate for the inositol 1,4,5-trisphosphate formation. This
leads to a synergistic increase in [Ca2]i in the presence of AVP,
which activates PLC- (12). In HIT-T15 cells, C3 exoenzyme
(10 g/ml), a Rho inhibitor isolated from Clostridium botuli-
num (40), and Ro31–8220 (10 M), a PKC inhibitor, did not
inhibit the SS-induced activation of PLD and its subsequent
increase PIP2 that leads to a synergistic increase in [Ca2]i. in
the presence of AVP.4 These findings suggest that SS-induced
PLD activation is not mediated by Rho or PKC and may be
mediated by another signaling protein.
In this paper, we focused on the role of Arf isoforms in the
regulation of SS-induced increase in PLD activity in an insulin-
secreting cell line, HIT-T15. Arfs are small G-proteins that play
an important role in vesicle transport, endocytosis, and actin
rearrangement (41) and insulin secretion (42). There are three
classes of Arf proteins (43). Class I (Arf1–3) play an important
role in Golgi vesicle transport. The role of Class II (Arf4, Arf5)
in cell signaling is not fully elucidated. Class III (Arf6) is located
in the plasma membrane and facilitates endocytosis pathways.
Arf6 also regulates cortical actin cytoskeleton arrangement and
has a profound effect on cell migration (44), wound healing
(45), and phagocytosis (46).
Like all smallG-proteins, Arf proteins switch from their inac-
tive GDP-bound state to their active GTP-bound state. The
intrinsic GTPase activity of Arf proteins is mainly affected by
GEFs and GTPase-activating proteins. GEFs enhance the dis-
sociation rate of GDP fromArfs, which is the rate-limiting step
in Arf activation. GTPase-activating proteins increase the
intrinsic GTPase activity of Arf, switching them back to their
GDP-bound inactive state.
There are several well defined hypotheses for GPCR activa-
tion of Arf proteins. Evidence suggests that Arf1 and Arf6 can
directly interact with the COOH terminus of GPCRs and
become activated upon stimulation of the receptors (33, 47).
Other studies indicate that Arf6 binds to -arrestin and
becomes activated byARNO, aGEF for bothArf1 andArf6 (35).
In this paper, we report that inHIT-T15 cells, SS utilizes a novel
signaling pathway to regulate PLD activity. We hypothesize
that in HIT-T15 cells 1) SS receptor mediates release of
-dimer signals through Arf6 to activate PLD, and 2) Arf6
activation by SS receptors is mediated by EFA6A, a low molec-
ular weight GEF of Arf6, thought to be primarily found in the
brain (48).
EXPERIMENTAL PROCEDURES
Cell Culture and Transfection—HIT-T15 cells were main-
tained in RPMI 1640 with 10% FBS and aerated with 5% CO2,
95% air at 37 °C. All experiments were performed using cells
from passages 80–90. pXS plasmids expressing wild type Arf6,
and dominant-negative (dn) constructs of Arf6 [Arf6(T27N)],
Arf1 [Arf1(T31N)], and Arf5[Arf5(T31N)] were generated as
described previously (49).
EFA6A wild type and EFA6A(E242K), EFA6B wild type and
EFA6B (E651K), andARNOwild type andARNO (E156K)were
inserted into pFLAG-cmv6 (Sigma) with the FLAG epitope at
the amino terminus (50). All plasmids were transfected into
HIT-T15 cells using LipofectamineTM (Invitrogen) according
to the manufacturer’s protocol.
Transfection with siRNA of Arf6 and EFA6A—The siRNA
sequences targeting Arf6 are GCACCGCAUUAUCAAU-
GACCG (sense, 5 to 3) and CGGUCAUUGAUAAUGCG-
GUGC (antisense, 5 to 3) (51). The siRNAsequences targeting
EFA6A are AUUGGUGGCUGGCGAGUAUUU (sense, 5 to
3) and AUACUCGCCAGCCAAUUU (antisense 5 to 3) (52)
and were manufactured by Dharmacon, Lafayette, CO. Cells
were platedwith 50% confluence in a T-25 flask andwere trans-
fected with siRNA on the second day of plating using Lipo-
fectamineTM and slightly modified transfection protocol.
Briefly, 25 l of 20 M Arf6 siRNA or 40 l of 20 M EFA6A
siRNA was diluted in 0.5 ml of RPMI 1640, and 15 l of Lipo-
fectamineTM was diluted in another tube in 0.5 ml of RPMI
1640 with gentle mixing. The RPMI 1640 used for transfection
had no FBS. After allowing them to stand for 10 min both mix-
tures were combined and mixed with gentle inversion. The
complex mixture was incubated for 20 min and then the entire
transfection mixture was added to the T-25 flask containing
fresh RPMI 1640 with 5% FBS. After 6 h of incubation, the
medium was replaced with regular RPMI 1640 containing 10%
FBS. 48 h after transfection the cells were distributed into
12-well plates for subsequent studies. The PLD assays and pro-
tein assays were performed72 h after transfection.
Northern Blot Analyses—Total RNA was isolated from HIT-
T15 cells using TRI Reagent (Sigma), and this total RNA was
used to make a HIT-T15 cDNA PCR template using the
SMART RACE cDNA Amplification Kit (BD Biosciences)
according to manufacturer’s instructions. Primers were
designed from rat EFA6A sequence (corresponding to base
pairs 844–1393 of complete coding sequence) and used in a
PCR reaction with the HIT-T15 cDNA template to amplify a
fragment of the EFA6A encoding gene from that tissue. Ampli-
fication of the desired target was confirmed by DNA sequenc-
ing. Northern blot riboprobes were generated by subcloning
this HIT-T15 EFA6A fragment into pGEM-T Easy (Promega,4 J. A. Grodnitzky and W. H. Hsu, unpublished data.
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Madison, WI), confirming orientation and fidelity with DNA
sequencing, then linearizing the plasmid with appropriate
restriction enzymes and transcribing probes with either T7 or
SP6 polymerase using MEGAscript Kit (Ambion, Austin, TX).
Probes were digoxigenin-labeled by incorporating digoxigenin
RNA labeling mix (Roche Applied Science) into this reaction.
For Northern blot, total RNA was isolated from HIT-T15 cells
and rat brain using TRI Reagent. For each sample, 1 g total
RNA was separated on a 1% agarose MOPS/formaldehyde gel
using standard protocols before being transferred to positively
charged nylon membrane (Roche Applied Science). The mem-
brane was probed before stringent washes and chemilumines-
cent detection with CDP-Star (Roche Applied Science).
Western Blot Analyses—Rabbit polyclonal antibodies were
raised against aCOOH-terminal peptide ofArf6, residues 164–
175, and against a NH2-terminal peptide of EFA6A (residues
4–18; KSPVPFLPGTSPSAD), respectively. The specificity of
the antibody was assessed byWestern blotting of cells express-
ing FLAG-tagged GEF constructs. Lysates were separated by
SDS-PAGE and blots probed with antibodies to EFA6A or
FLAG and visualized with secondary antibodies using Odyssey
Infrared Imaging System (Li-Cor, Lincoln, NE). Rabbit poly-
clonal antibodies raised against Arf1 were a generous gift of Dr.
Richard Kahn of Emory University School of Medicine. Ten g
of whole cell HIT-T15 protein was separated by reduced SDS-
PAGE (10%). Protein for Arf analysis was transferred to PVDF
membranes in transfer buffer (35mMTris, 190mM glycine, 20%
methanol), whereas protein for EFA6A analysis was transferred
to nitrocellulose membrane. The PVDF and nitrocellulose
membranes were blocked with 5% nonfat dry milk in phos-
phate-buffered saline for 1 h at room temperature. The primary
Arf antibodies were diluted 1:50 in wash buffer (0.01% Tween
20 in Tris-buffered saline), whereas the primary EFA6A anti-
bodieswere diluted 1:700 inwash buffer. The diluted antibodies
were incubatedwith the PVDFor nitrocellulosemembranes for
1 h at room temperature. The blots were washed three times
for 10 min each with wash buffer. The secondary antibody
(goat anti-rabbit IgG conjugated to horseradish peroxidase,
Pierce) was diluted 1:2,000 in wash buffer and incubated
with the PVDF or nitrocellulose membranes for 1 h at room
temperature. The blots were then washed and developed
using diaminobenzidine.
Determination of PLD Activity—PLD assay was performed
using a previously described method (53). Briefly, HIT-T15
cells were grown in 24-well plates overnight in RPMI 1640
medium with 10% FBS. The medium was then discarded and
500 l of 3 Ci/ml [3H]myristic acid (PerkinElmer Life Sci-
ences) was added to each well for 60 min. Cells were then
washed twice with Krebs-Ringer buffer before 400 l of
Krebs-Ringer buffer was added to each well. Treatments
were applied 15 s after the addition of 0.5% 1-butanol. The
reactions were terminated 30 s after SS had been adminis-
tered. Phosphatidylbutanol and phosphatidylbutanol were
identified by migration with unlabeled standards, visualized
by iodine staining and radiographed into 1-cm blocks, and
were subsequently scraped and radioactivity quantified by
liquid scintillation counting.
Data Analyses—All values are presented as mean  S.E.
Results were analyzed using analysis of variance and individual
mean comparisons were made using the Least Significant Dif-
ference test. The significance level was set at p 0.05.
RESULTS
Western Blot Analysis of Arf1 and Arf6—Arf1 and Arf6 have
been shown to stimulate PLD activity through GPCR signaling.
To determine the particular Arf isoform that may play a role in
FIGURE 1. A, Western blot analyses of Arf1 and Arf6 in HIT-T15 cells. 10 g of
the whole cell protein was separated using SDS-PAGE, transferred to PVDF
membrane, and blotted with 1:50 Arf1 and Arf6 antibodies. B, effect of
Arf6(T27N) expression on SS-induced increase in PLD activity. HIT-T15 cells
were transfected24hprior toPLDassay. Cellswere thenpretreatedwith0.5%
1-butanol 15 s prior to SS treatment. Experiments were terminated 30 s after
SShadbeenadministered. Values are themeanS.E. (n4 independent cell
preparations). *, p 0.05, compared with the control group. PBt, phosphati-
dylbutanol, PC, phosphatidylcholine.
FIGURE 2. Effect of Arf1(T31N) expression on SS-induced increase in PLD
activity. HIT-T15 cells were transfected 24 h prior to PLD assay. Treatment
procedures were the same as in Fig. 1B. Values are the mean  S.E. (n  4
independent cell preparations). *,p0.05, comparedwith the control group.
PBt, phosphatidylbutanol; PC, phosphatidylcholine.
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this SS-receptor signaling pathway, Western blot analysis was
performed to determine the Arf isoforms present in HIT-T15
cells. The results demonstrated the presence Arf1 and Arf6,
with sizes of20 kDa, in HIT-T15 cells (Fig. 1A).
Arf6, but Not Arf1, Mediates SS-
induced PLD Activation—Arf6 has
been previously shown to stimulate
PLD in other systems via a GPCR-
mediated pathway (26, 33–35). To
determine the involvement of Arf6
in PLD stimulation in HIT-T15
cells, we overexpressed various Arf6
mutants and analyzed their effect
on SS-induced increase in PLD
activity. Protein expression of the
HA-tagged Arf6 mutant was deter-
mined by immunocytochemistry
(ICC) using anti-HA monoclonal
antibodies with 80–90% of HIT-
T15 cells expressing the HA
epitope (data not shown). SS (100
nM) increased PLD activity
2-fold (Fig. 1B). Overexpression
of dn-Arf6 mutant Arf6(T27N)
abolished SS-induced increase in
PLD (Fig. 1B). Furthermore, overex-
pression of Arf6(T27N) did not
affect base-line PLD activity (Fig.
1B). Arf1 is another well known reg-
ulator of PLD1 and has also been
demonstrated to stimulate PLD
activity via a GPCR-mediated
pathway (47) and was present in
HIT-T15 cells (Fig. 1A). To deter-
mine the involvement of Arf1 in
this signaling pathway, an Arf1 dn-
mutant Arf1(T31N) was overex-
pressed to determine its effects on
SS-mediated increase in PLD
activity. Protein expression of the
HA-tagged Arf1 mutant was
determined by ICC using anti-
HA monoclonal antibodies with
80–90% of HIT-T15 cells express-
ing the HA epitope (data not
shown). SS (100 nM) stimulation of
PLD was not affected by the over-
expression of Arf1(T31N) (Fig. 2).
Overexpression of Arf1(T31N) had
no effect on baseline PLD activity
either (Fig. 2). The above data sug-
gested that Arf6, but not Arf1, plays
a significant role in SS-induced
increase in PLD activity in HIT-T15
cells.
For the sake of completeness,
Arf5, a class II Arf also was exam-
ined. To determine the involvement
of Arf5 in this signaling pathway, an Arf5 dn-mutant
Arf5(T31N) was overexpressed to determine its effects on SS-
mediated increase in PLD activity. Protein expression of the
HA-tagged Arf5 mutant was determined by ICC using anti-HA
FIGURE 3. Effect of Arf5(T31N) expression on SS-induced increase in PLD activity. HIT-T15 cells were
transfected 24 h prior to PLD assay. Treatment procedures were the same as in Fig. 1B. Values are the mean
S.E. (n 3 independent cell preparations). *, p 0.05, comparedwith the control group. PBt, phosphatidylbu-
tanol; PC, phosphatidylcholine.
FIGURE 4. A, Western blot analyses of Arf6 in HIT-T15 cells transfectedwith siRNA. Themethodswere the same
as Fig. 1A. B, suppression of Arf6 expression by transfecting cells with Arf6 siRNAon SS-induced increase in PLD
activity. HIT-T15 cells were transfected for72 h prior to PLD assay. Treatment procedureswere the same as in
Fig. 1B. Values are themeanS.E. (n3 independent cell preparations). *,p0.05, comparedwith the control
group. PBt, phosphatidylbutanol; PC, phosphatidylcholine.
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monoclonal antibodies with 80–90% of HIT-T15 cells express-
ing theHAepitope (data not shown). SS (100 nM) stimulation of
PLDwas not affected by the overexpression ofArf5(T31N) (Fig.
3). Over-expression of Arf5(T31N) had no effect on base-line
PLD activity either (Fig. 3).
To confirm the effect of Arf6 on SS-induced PLD activation,
we transfected cells with siRNA for Arf6. Transfection with
siRNA reduced Arf6 expression to 20% of the control level
(Fig. 4A). SS-induced PLD activation was abolished in these
transfected cells (Fig. 4B). These results suggest that Arf6medi-
ates SS-induced activation of PLD.
Overexpression of wild type Arf6 enhanced SS (100 nM)-in-
duced increase in PLD activity but did not change baseline PLD
activity (Fig. 5). These results suggested that SS stimulation of
PLD activity is mediated through an Arf6-dependent pathway.
EFA6, but Not ARNO, Mediates SS-induced PLD Activation—
ARNO is one of themembers of the ARNO/cytohesin family of
low molecular weight GEFs that are known to increase Arf
activity and cause a subsequent increase in PLD activity
through a GPCR-signaling pathway (34, 35, 54). To examine
whether ARNO may play a role in the SS-induced increase in
PLD activity, the dn-mutant of ARNO (ARNO(E156K)) was
overexpressed. Protein expression of the FLAG-tagged ARNO
mutant was determined by ICC using anti-FLAG monoclonal
antibodies with 80–90% of HIT-T15 cells expressing the FLAG
epitope (data not shown). Overexpressing ARNO(E156K) had
no effect on SS-induced increase in PLD activity nor was basal
activity of PLD affected (Fig. 6). These results suggested that
ARNO does not play a significant role in SS-mediated activa-
tion of PLD.
The EFA6 family of GEFs acts specifically on Arf6 (55) but
has not yet been reported to stimulate PLD through GPCR
stimulation. To determine whether EFA6GEFs function in this
signaling pathway, HIT-T15 cells were transfected with the dn-
mutant of EFA6A (EFA6A(E242K)), thought to be a neural-
specific isoform (56), and the dn-EFA6B (EFA6B(B651K)),
thought to be a widely expressed isoform (48). Protein expres-
sion of the FLAG-tagged EFA6A and EFA6B mutants was
determined by ICC using anti-FLAG monoclonal antibodies
with 80–90% of HIT-T15 cells expressing the FLAG epitope
(data not shown). Overexpression of dn-EFA6A abolished SS-
induced PLD activation, whereas that of dn-EFA6B failed to do
so (Fig. 7). Overexpressing these EFA6 dn-mutants did not
change basal PLD activity.
EFA6A Expression—To confirm that EFA6A may play a role
in this SS-receptor signaling pathway, both Northern and
Western blot analyses were performed to determine if this
EFA6A isoform is present inHIT-T15 cells. Northern blot anal-
yses demonstrated the presence of mRNA of EFA6Awith a size
of 2.1 kb in both rat brain and HIT-T15 cells (Fig. 8A). In
addition, a size of 1.6 KB EFA6A mRNA was found in HIT-
T15 cells. Western blot analyses demonstrated the presence of
EFA6A with a size of 70 kDa in both HIT-T15 cells and rat
brain homogenate (Fig. 8B). In addition, a smaller EFA6A pro-
tein with a size of 40 KDa was detected in both samples; the
nature of this band is unclear, but it could be a breakdown
product or an isoform of EFA6A.
The antibody directed against EFA6A was specific for this
GEF, since it did not detect transfected, FLAG-tagged EFA6B,
EFA6C, or ARNO, although these GEFs were visible with anti-
FLAG antibodies (Fig. 8C).
Inhibition of EFA6A Expression on SS-induced PLD
Activation—To confirm the effect of EFA6A on SS-induced
PLD activation, we transfected cells with siRNA for EFA6A.
Transfection with siRNA reduced EFA6A expression to40%
of the control level (Fig. 9A). SS-induced PLD activation was
abolished in these transfected cells (Fig. 9B). These results sug-
gested that EFA6A is essential for SS-induced activation of PLD
and provided further evidence for the involvement of Arf6 in SS
receptor signaling pathway.
DISCUSSION
The findings of the present study strongly support the
hypothesis that Arf6 mediates the SS-induced increase in
PLD activity in clonal -cells HIT-T15. Despite the fact that
both Arf1 and Arf6 are present in these cells, the effects of
overexpression of dn-mutant and wild type Arf6 as well as
FIGURE 5. Effect ofwild type (wt)-Arf6 expression on SS-induced increase
onPLDactivity.HIT-T15 cells were transfected 24 h prior to PLD assay. Treat-
ment procedures were the same as in Fig. 1B. Values are themean S.E. (n
4 independent cell preparations). *, p  0.05, compared with the control
group and **, p  0.05, compared with the SS alone group. PBt, phosphati-
dylbutanol; PC, phosphatidylcholine.
FIGURE 6. Effect of ARNO(E156K) expression on SS-induced increase on
PLD activity. HIT-T15 cells were transfected 24 h prior to PLD assay. Treat-
ment procedures were the same as in Fig. 1B. Values are themean S.E. (n
4 independent cell preparations). *, p  0.05, compared with the control
group. PBt, phosphatidylbutanol; PC, phosphatidylcholine.
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transfection with Arf6 siRNA on SS-induced PLD activation
indicate that Arf6 is essential for this pathway. In addition,
this effect does not seem to be an artifact of the overexpres-
sion of an Arf protein, because overexpression of dn-Arf1 or
dn-Arf5 mutant did not have any effect on SS-induced PLD
activation.
The EFA6 family consists of four
related Arf6 GEFs (A, B, C, and D)
that contain similar Sec7 and pleck-
strin homology domains and are
distinguished by variable amino-
terminal extensions. The EFA6B
isoform is widely expressed, while
the EFA6A isoform is more promi-
nent in brain (48). Nevertheless,
using probes specific for EFA6A, we
detected by Northern analysis a
band of 2.1 kb in both rat brain
andHIT-T15 cells, which is consist-
ent with the predominant 2.1 kb
species reported in brain, small
intestine, colon, and ovary (48). In
addition, the EFA6A protein of the
expected size, 70 kDa, was
observed with EFA6A-specific anti-
serum. We also detected a shorter
mRNA of EFA6A of 1.6 kb. Our
findings are interesting, because
EFA6A, and not EFA6B, is specifi-
cally involved in the SS-induced
PLD activation in clonal-cells, and
this will be further explored.
The ability of the EFA6A dn-mu-
tant, EFA6A(E242K), and siRNA for
EFA6A to block SS-induced PLD
activation further implicates the
involvement of Arf6 and places an
EFA6 family GEF, but not ARNO, in
mediating SS-induced activation of
PLD. Taken together, these findings
strongly suggest the involvement
of EFA6A-Arf6 in this signaling
pathway.
We previously demonstrated that
SS was able to increase PLD activity
inHIT-T15 cells, leading to a subse-
quent increase in PIP2 levels (12). In
this paper we report a novel mecha-
nism for PLD stimulation. In our
proposed model, the -dimer that
couples to SS receptors interacts
directly or indirectly with EFA6A,
which is known to increase the
nucleotide exchange rate on Arf6.
Arf6-GTP would activate PLD1 in
HIT-T15 cells. Although our pro-
posed model for GPCR-mediated
activation of theArf6-PLD signaling
cascade is similar to other previously reported models, distinct
differences between the models are apparent. In one proposed
model the -dimer directly interacts with Arf1 and Arf4, a
Class II Arf (36). In our system, Arf1 and Arf5, another Class II
Arf, did not play a significant role in the SS-induced activation
of PLD, indicating that the direct interaction of -dimer with
FIGURE 7. Effect of overexpression of dn-mutants of EFA6, EFA6A(E242K), and EFA6B(E651K) on SS-
induced increase on PLD activity.HIT-T15 cells were transfected 24 hwith EFA6A(E242K) and EFA6B(E651K),
respectively, prior to PLD assay. Treatment procedures were the same as in Fig. 1B. Values are themean S.E.
(n 4 independent cell preparations). *,p 0.05, comparedwith the control group. PBt, phosphatidylbutanol;
PC, phosphatidylcholine.
FIGURE 8.Northern (A) andWestern (B) blot analyses of EFA6A in native HIT-T15 cells and rat brain. A, 1
g of total RNA was separated using 1% agarose gel and then transferred to positively charged nylon mem-
brane. Themembranewasprobedwith a fragmentof theEFA6Acodinggene.B, 12gof thewhole cell protein
was separated using SDS-PAGE, transferred to a nitrocellulose membrane, and blotted with 1:700 EFA6A
antibodies. Negative controls did not have antibody versus EFA6A. C, characterization of antibody versus
EFA6A. HeLa cells were transfected with FLAG-tagged constructs encoding EFA6A, an amino-terminally trun-
cated EFA6A (N), EFA6C, EFA6B, or ARNO. Lysates of cells were loaded onto SDS-PAGE and blots probedwith
antibodies to EFA6A (top panel) or FLAG (lower panel).
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Class I/II Arfs does not occur in the HIT-T15 cell system for
SS-PLD signaling.
There have been several reports of GPCR activation of Arf6
occurring due to the ability of Arf6 to directly interact with
activated GPCRs. This signaling cascade has been demon-
strated in 5-hydroxytryptamine-2A receptors (47), gonado-
tropin-releasing hormone receptors (28), and M3-muscarinic
receptors (26). These studies show the involvement of Arf1,
Arf3, and Arf6 in the GPCR-mediated activation of PLD. This
signaling cascade is dependent on Arf proteins interacting with
the NPXXY motif located in the seventh transmembrane helix
of these receptors (33, 57). NPXXY is a commonmotif found in
mostGPCRs and is found inType 2 SS receptor, the SS receptor
present in HIT-T15 cells that mediate the effect of SS in these
cells (58). These studies demonstrate that the activation of a
GPCR can stimulate the conversion of Arf-GDP to its active
Arf-GTP-bound state; Arf-GTP can then bind to the NPXXY
motif of the receptor. The direct binding model does not con-
flict with the results obtained from this study. The focus of this
study was to determine the proteins involved in SS-induced
activation of PLD and we did not address the translocation or
scaffolding properties of activated Arf6 in this paper. It is pos-
sible that the -dimer interacts with EFA6A to switch Arf6 to
the GTP bound state. Furthermore, the active Arf6 could then
bind toNPXXYmotif of an activated SS receptor, whichmay be
essential for PLD activity. Addi-
tional studies are required to deter-
mine whether a direct interaction
transpires between SS receptors and
Arf6-GTP.
In our proposed model, the
mechanism of SS-induced activa-
tion of PLD in HIT-T15 cells is
through the -dimer (12). We
hypothesize that the -dimer cou-
pling to SS receptor interacts with
EFA6A, which will cause a subse-
quent stimulation of PLD1 in HIT-
T15 cells through Arf6 activation.
This study provides an exciting
novel signal mechanism upon
which SS can activate PLD. Another
well documented model for GPCR-
mediated activation of Arf6 involves
the stimulation of -adrenergic
receptors (34) and luteinizing hor-
mone receptors (35). Activation of
these receptors leads to the dissoci-
ation of -dimer and subsequent
activation of G-protein-coupled
receptor kinase. G-protein-coupled
receptor kinase then phosphoryl-
ates the receptors, which recruits
-arrestin to the receptor and leads
to receptor desensitization (34).
Upon -arrestin binding, ARNO
scaffolds with the desensitized
receptor complex, thereby activat-
ing Arf6. The twomain differences between the models are the
GEFs involved in Arf6 activation and the additional down-
stream signaling events that occur after the dissociation of
-dimer. In our system, EFA6A controls the SS-induced acti-
vation of PLD. In the othermodel ARNO is responsible for Arf6
activation (34). Surprisingly, in HIT-T15 cells, EFA6A domi-
nated this signaling cascade, and ARNO did not significantly
contribute to this pathway. These results indicate that in HIT-
T15 cells EFA6A, but not ARNO, is essential for the activation
of Arf6. An alternative hypothesis would be that additional sig-
naling events occur between the -dimer and EFA6A. Such
events are likely to include the involvement of G-protein-cou-
pled receptor kinases and -arrestins.
Although this study provides an exciting novel signal mech-
anismuponwhich SS can activate PLD1 and cause a subsequent
increase in PIP2, the physiological significance for SS-induced
activation of Arf6 and PLD1 is not well understood. Arf6-in-
duced increase in PIP2 levels has been reported in another pan-
creatic-cell line,MIN6, inwhich the ability of Arf6 to increase
PIP2 levels was essential to the slow phase of insulin secretion
but had no effect on initial fast phase of insulin secretion (42). In
addition, PLD1 activation has been shown to be essential for
insulin secretion for both glucose and cholinergic receptor-me-
diated responses (61, 62). The action of PLD1 on exocytosis
appears to mediate its effect through a distal step of exocytosis,
FIGURE 9. A, Western blot analyses of EFA6A in HIT-T15 cells transfected with siRNA forEFA6A. The methods
were the same as Fig. 1A. B, suppression of EFA6A expression by transfecting cells with EFA6A siRNA on
SS-induced increase in PLD activity. HIT-T15 cells were transfected for 72 h prior to PLD assay. Treatment
procedureswere the sameas in Fig. 1B. Values are themean S.E. (n 3 independent cell preparations). *,p
0.05, compared with the control group. PBt, phosphatidylbutanol; PC, phosphatidylcholine.
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somewhere beyond vesicle recruitment and the readily releas-
able pool. Both Arf6 and PLD1 stimulate exocytotic processes
in -cells, so we are perplexed as to why an inhibitory hormone
like SS would signal through Arf6-PLD1 pathway. On the other
hand, we recently found that SS evoked its receptor endocyto-
sis.5 Since activation of Arf6 (34) and PLD (59, 60, 63) can
induce receptor endocytosis, we hypothesize that this novel sig-
naling pathwaymediates SS receptor endocytosis. Furtherwork
is underway to test this hypothesis.
This study describes for the first time the involvement of
EFA6A in a GPCR signaling pathway and the presence of
EFA6A in insulin-secreting cells. In addition, Western blot
analysis using antibodies that recognize the NH2 terminus of
EFA6A detected endogenous EFA6A in HIT-T15 cells. Taken
together with our findings with Northern and Western blot
analyses, this is evidence for the existence of EFA6A in HIT-
T15, although further studies will be required to explore the
implications of this signaling pathway in insulin-secreting cells.
Acknowledgment—Dr. Quangxing Bai is acknowledged for contribu-
tion to preliminary data on Arf6 Western blot analysis.
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